Author

Frank Seeliger

AstraZeneca (Sweden)ORCID 0000-0003-0565-951XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:variant calling· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

Lorenz M. Mayr· 2 shared Marcello MarescaiD· 2 shared Michelle J. PorrittiD· 2 shared Mohammad Bohlooly‐YiD· 2 shared Roberto NitschiD· 2 shared Abdel Wahad Bidar· 1 shared Alba CarrerasiD· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Lorenz M. Mayr

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GenomicsbioRxivPreprintApr 6, 2020

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal…·Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

2 citations

mousehuman

𝕏 PostBluesky

Molecular BiologyNaturePeer-reviewedSep 1, 2018

In vivo CRISPR-Cas gene editing with no detectable genome-wide off-target mutations

Pınar Akçakaya, Maggie L. Bobbin, Jimmy A. Guo…·J. Keith Joung

The paper introduces VIVO, a method to detect off-target mutations from in vivo CRISPR-Cas editing, showing that well-designed gRNAs can edit efficiently without detectable off-targets.

322 citationstop 1%

humanCRISPR screen

𝕏 PostBluesky